- Home
- CHAC vs AVIR Comparison
CHAC vs AVIR Comparison
Compare CHAC & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHAC
- AVIR
- Stock Information
- Founded
- CHAC 2025
- AVIR 2012
- Country
- CHAC United States
- AVIR United States
- Employees
- CHAC N/A
- AVIR N/A
- Industry
- CHAC
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- CHAC
- AVIR Health Care
- Exchange
- CHAC NYSE
- AVIR Nasdaq
- Market Cap
- CHAC 300.0M
- AVIR 273.0M
- IPO Year
- CHAC 2025
- AVIR 2020
- Fundamental
- Price
- CHAC $10.06
- AVIR $3.67
- Analyst Decision
- CHAC
- AVIR Hold
- Analyst Count
- CHAC 0
- AVIR 1
- Target Price
- CHAC N/A
- AVIR $6.00
- AVG Volume (30 Days)
- CHAC 13.1K
- AVIR 410.2K
- Earning Date
- CHAC 01-01-0001
- AVIR 08-06-2025
- Dividend Yield
- CHAC N/A
- AVIR N/A
- EPS Growth
- CHAC N/A
- AVIR N/A
- EPS
- CHAC N/A
- AVIR N/A
- Revenue
- CHAC N/A
- AVIR N/A
- Revenue This Year
- CHAC N/A
- AVIR N/A
- Revenue Next Year
- CHAC N/A
- AVIR N/A
- P/E Ratio
- CHAC N/A
- AVIR N/A
- Revenue Growth
- CHAC N/A
- AVIR N/A
- 52 Week Low
- CHAC $9.98
- AVIR $2.46
- 52 Week High
- CHAC $11.28
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- CHAC N/A
- AVIR 76.11
- Support Level
- CHAC N/A
- AVIR $3.15
- Resistance Level
- CHAC N/A
- AVIR $3.35
- Average True Range (ATR)
- CHAC 0.00
- AVIR 0.13
- MACD
- CHAC 0.00
- AVIR 0.03
- Stochastic Oscillator
- CHAC 0.00
- AVIR 83.81
About CHAC CRANE HBR ACQUISITION CORP
Crane Harbor Acquisition Corp is a blank check company.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).